Wet AMD risk linked to sleep apnea
sleep apnea

Wet AMD risk linked to sleep apnea

Researchers at the Center for Eye Research in Australia have discovered a possible link between moderate-to-severe obstructive sleep apnea (OSA) and wet age-related macular degeneration.
Study finds that AREDS 2 supplementation helps slow progression of late-stage macular degeneration
AMD

Study finds that AREDS 2 supplementation helps slow progression of late-stage macular degeneration

While researchers have known that AREDS 2 supplements help slow the progression of AMD from the intermediate stage to the late stage, they wanted to establish whether supplementation could impact t...
Researchers working on possible alternative treatment for wet AMD
age-related macular degeneration

Researchers working on possible alternative treatment for wet AMD

Researchers have recently discovered that the enzyme, telomerase, plays a role in abnormal blood vessel formation in lab mice and this discovery may lead to new therapies in treating the wet form ...
New AMD drug completes Phase 2 trial
EyePoint

New AMD drug completes Phase 2 trial

EyePoint Pharmaceuticals announced the completion of the Phase 2 trial of their new experimental drug, vorolanib, for the treatment of wet age-related macular degeneration.
New eye drops may be potential new treatment for wet AMD
intravitreal injection

New eye drops may be potential new treatment for wet AMD

The current available therapies available to treat wet AMD involve intravitreal injections delivered every month to the back of the eye. 
Regeneron receives FDA approval for EYLEA HD
diabetic macular edema

Regeneron receives FDA approval for EYLEA HD

The Food and Drug Administraton (FDA) gave approval after two active-controlled, double-masked pivotal trials, which compared EYLEA HD to EYLEA over a 48 week period.
FDA approves Izervay for treatment of geographic atrophy
AMD

FDA approves Izervay for treatment of geographic atrophy

The Food and Drug Administration (FDA) recently announced their approval of Izervay for treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
New anti-VEGF therapy shows promise in Phase 1 Clinical trial
anti-VEGF

New anti-VEGF therapy shows promise in Phase 1 Clinical trial

The new drug is manufactured by 4D Molecular Therapeutics and is a dual-transgene intravitreal gene therapy.
AI algorithm may be a helpful tool for determining progression of AMD
AMD

AI algorithm may be a helpful tool for determining progression of AMD

Artificial intelligence may be the key in helping doctors determine which patients with intermediate AMD are at a high risk of the disease progressing to geographic atrophy.